Neumora Therapeutics (NMRA) Capital Expenditures (2022 - 2023)
Neumora Therapeutics (NMRA) posted quarterly Capital Expenditures of $44000.0 for Q4 2023, down 90.93% year-over-year from $485000.0 in Q4 2022, and up 18.92% quarter-over-quarter from $37000.0 in Q3 2023.
Neumora Therapeutics (NMRA) Capital Expenditures (2022 - 2023) Analysis & Trends
Neumora Therapeutics' Capital Expenditures history runs 2 years deep, the most recent figure standing at $44000.0 for Q4 2023.
- In Q4 2023, Capital Expenditures fell 90.93% year-over-year to $44000.0; the TTM figure through Dec 2023 stood at $117000.0 (changed N/A YoY), while the FY2023 annual figure was $117000.0, down 76.83% from the prior year.
- Capital Expenditures for Q4 2023 stood at $44000.0, up from $37000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $485000.0 in Q4 2022, with the low at $36000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 44,000.00 |
| Dec 31, 2023 | 44,000.00 |
| Sep 30, 2023 | 37,000.00 |
| Sep 30, 2023 | 37,000.00 |
| Mar 31, 2023 | 36,000.00 |
| Mar 31, 2023 | 36,000.00 |
| Dec 31, 2022 | 485,000.00 |
| Dec 31, 2022 | 485,000.00 |